Market Assessment
The study integrates60 structured interviews(qualitative deep dives) and300 online surveys(quantitative validation) with stakeholders across the healthcare value chain — including hospitals, clinics, and patients. Coverage spans major cities in the UAE.
| Customer Cohort | Description | Proposed Sample Size |
|---|---|---|
| Healthcare Professionals | Doctors and specialists involved in Crohn's Disease treatment | Sample Size: 80 |
| Patients with Crohn's Disease | Individuals diagnosed with Crohn's Disease | Sample Size: 100 |
| Pharmaceutical Representatives | Sales representatives from companies providing Crohn's Disease therapies | Sample Size: 50 |
| Healthcare Administrators | Decision-makers in hospitals and clinics | Sample Size: 70 |
| Insurance Providers | Representatives from health insurance companies | Sample Size: 50 |
| Researchers and Academics | Experts studying Crohn's Disease | Sample Size: 30 |
Total Respondents:360 (60 structured interviews+300 surveys)
Crohn's Disease is a chronic inflammatory bowel disease affecting the gastrointestinal tract. In the UAE, diagnosis typically involves a combination of endoscopy, imaging techniques (like MRI and CT), biopsies, and laboratory tests to assess inflammation and rule out other conditions.
Treatment options for Crohn's Disease in the UAE include medical management with anti-inflammatory drugs, biologic therapies, nutritional support, and surgical procedures for severe cases. The choice of treatment depends on disease severity and patient-specific factors.
The prevalence of Crohn's Disease in the UAE is increasing, driven by factors such as lifestyle changes and dietary habits. Awareness and education about the disease are also growing, contributing to more diagnoses and better management strategies.
Recent advancements in Crohn's Disease diagnostics in the UAE include improved imaging technologies, enhanced endoscopic techniques, and the development of non-invasive laboratory tests. These innovations aim to increase diagnostic accuracy and patient comfort during the evaluation process.
Patients in the UAE face challenges such as high treatment costs, limited access to specialized healthcare providers, and variability in diagnostic accuracy. These factors can hinder timely and effective management of Crohn's Disease.
